In the past, it was believed that the main reason for the difference in clinical prognosis between Asian and non-Asian gastric cancer patients was the adoption of different treatment methods and clinical management methods. However, a recent clinical trial shows that even if standard treatment methods are used, there are still differences in clinical prognosis between Asian and non-Asian gastric cancer patients.
A transnational research team from the Singapore Genome Research Institute conducted the clinical study and found that the difference in clinical prognosis of gastric cancer is related to the different tumor immune markers between patients from Asian and non-Asian countries.
The results show that, There are different gene markers between Asian and non-Asian gastric cancer patients, These gene markers are mainly related to immune function and inflammatory response. The results suggest that, Different regional factors will affect the tumor immune markers of gastric cancer patients, resulting in different clinical results. The study also found that the difference between tumor immune markers of Asian and non-Asian gastric cancer patients will lead to the difference in survival rate of gastric cancer patients in different regions.
From this study, in the future cancer research, especially in the aspect of tumor immunology, we should pay attention to the influence of regional factors on cancer and achieve individualized intervention therapy to achieve the best therapeutic effect.
The author of this article [Hou Qiuke] originated from Clove Garden and is slightly abridged.